PLASMA THYMUS & ACTIVATION-REGULATED CHEMOICINE (TARC) AND MONOCYTE-DERIVED CHEMOICINE (MDC) LEVELS IN CHRONIC ASTHMATIC PATIENTS DEVELOPED ACUTE EXACERBATION
|Full paper||Not Available|
Objectives: The present study was designed to measure the plasma levels of Thymus and activation-regulated chemokine (TARC) and monocyte-derived chemokine (MDC) in chronic asthmatic patients who required hospitalization for an acute exacerbation. Patients & Methods: The. study included 40 patients; 2,99nales and II females with mean age 49.7+7 years. Al 1 patients had acute exacerbation of chronic bronchial asthma, and underwent clinical and radiological evaluation. Venous blood samples were obtained at time of admission (Day-0) and 4-weeks after inclusion in the study (Day-28) for EL1SA estimation of plasma levels of TARC and MDC. Results: Mean plasma levels of TARC estimated at time of admission (78.9+30.6; range: 43- 175 pg/ml) were significantly higher (p<0.001 , Z=5.380,) compared to levels estimated at 4-weeks after admission (35±12.8; range: 15-62 pg/ml ). Similarly, mean plasma levels of MDC estimated at time of admission (759.7+227.4; range: 387-1350 pg/ml) were significantly higher (p<0.001, Z=5.511) compared to levels estimated at 4-weeks after admission (289+1172; range: 100-650 pg/m1). There was a significant positive correlation (p=0.003 , r=0.457) between plasma TARC and MDC levels at admission. Both parameters showed positive correlation with total score of associated conditions. Howe vet; he correlation with TARC was significant (p=0.001, r=0.490). Plasma TARC levels were significantly correlated with the presence of upper respiratory tract infection, (p=0.014 , r=0.38.5) and social status and special habits, (p=0.011 , r=0.399). The presence of reflux symptoms associated with chronic asthma was significantly correlated with plasma MDC, (p=0.048 , r=0.314). Conclusion: Elevation of plasma levels of both MDC and TARC reflect their role in pathogenesis of acute exacerbation of chronic asthma and could predict its response to steroid therapy.